Total growth of transplanted human or rodent tumors in the subrenal capsule of mice was much improved by treatment with cyclosporine (CSA, cyalosporin A). Tumor size increased rapidly between days 6 and 12 after implantation. CSA injected on days 1-5 or 2-8 prevented tumor regression. In contrast, immulolQgic regression occurred after 6 days in absence of the drug. Seyeral assays for growth in vitro of clonogenic human tumor cells have been developed, and these may be useful for certain tumor types. However, results with these methods have not been easily reproducible, and many human tumors give cloning efficiencies too low to evaluate (2). Moreover, clonogenic assays do not provide a system to study (i) toxicity of drugs to normal tissues, (ii) host responses to tumor growth, or (iii) localization or activation of drugs and other agents in tumor vs. normal tissues. Monoclonal antibodies and angiogenesis inhibitors are two promising therapeutic approaches that cannot be evaluated by clonogenic assays.
or normal mice with syngeneic rodent tumors. Studies with rodent tumors in syngeneic mice showed that the CSA treatments had no antitumor effect. Inflammatory infiltration was seen on days 6-12 after tumor implantation into control mice. Immunoperoxidase staining showed murine T cells to be prominent in the infiltrate. In contrast, tumors in CSA-treated mice contained minimal inflammqtory infiltrate even 12 days after implantation. Allogeneic tumors in CSA-treated mice caused neovqscularization, metastases, and local invasion into the kidney. cis-Diamminedichloroplatinum showed highly significant activity against human tumors in CSA-treated mice during the period 6-10 days after tumor implantation but showed no statistically significant antitumor activity 0.6 days after implantation in mice not treated with CSA. We suggest that in CSA-treated mice the subrenail capsule assay for tumor growth provides a rapid, economical model for investigations in vivo of mouse or human tumor biology, for drug screening with a standard tumor, or for determination of optimal treatment of particular human tumors.
The ability to grow human tumors outside of the natural host has been a continuous challenge for investigations of human tumor biology, for development of antineoplastic drugs, and for selection of optimal therapy based on specific drug sensitivities of clinical tumor samples. Although many curative treatments for rodent tumors have been demonstrated in laboratory models, it is often difficult to transfer such promising results from animal models into clinical therapy with significant benefit for patients with cancer. In contrast to rodent tumors, which grow readily in numerous test systems, human tumors are difficult to propagate in laboratory models for testing cancer therapeutic agents (1 Seyeral assays for growth in vitro of clonogenic human tumor cells have been developed, and these may be useful for certain tumor types. However, results with these methods have not been easily reproducible, and many human tumors give cloning efficiencies too low to evaluate (2) . Moreover, clonogenic assays do not provide a system to study (i) toxicity of drugs to normal tissues, (ii) host responses to tumor growth, or (iii) localization or activation of drugs and other agents in tumor vs. normal tissues. Monoclonal antibodies and angiogenesis inhibitors are two promising therapeutic approaches that cannot be evaluated by clonogenic assays.
Subcutaneous implantation of human or rodent tumors into athymic nude mice is an alternative method for investigations of tumor-host interactions and new treatment strategies. This technique, although generally usable, is time-consuming, and nude mice and the facilities necessary to maintain them are expensive enough to limit its practicality (3) .
The subrenal capsule (SRC) assay developed by Bogden and coworkers (3, 4) permits precise in situ measurement of transplanted human tumors by use of a stereomicroscope with an ocular micrometer. Beneath the transparent renal capsule of mice is an advantageous site for delivery of nutrients, drugs, or other substances to the implanted tumor. In contrast to the subcutaneous sit', which often requires weeks or months for appreciable tumor growth, in nude mice the SRC assay can quantify small changes in tumor size after 6-12 days.
With normal mice, a 6-day protocol is used for the SRC assay; this is an attempt to avoid the period of greatest immunologic regression, which occurs 6-12 days after tumor implantation (4) . A comparison (5) of the SRC assay with a human tumor cloning method (bilayer soft agar) developed by Hamburger and Salmon (6) showed that the SRC method gave about twice as many evaluable assays. This observation suggests that the subcapsular site is a more favorable medium for growth of solid human tumor explants than is soft agar. Initial studies with fresh surgical explants of human cancers in the 6-day SRC assay also indicate a high success rate for several common human tumors, exceeding 80% for breast, ovarian, lung, and colon cancers (7 Proc. Natl. Acad Sci. USA 81 (1984) Proc. Natl. Acad ScL USA 81 (1984) 7929 1) mice and in athymic nude mice (Fig. 1) (12.5 omu) . In contrast, the tumors on day 10 in CSA-treated mice were ==30 omu, an increase of -130%. The growth rate of tumors during days 6-10 was greater than during days 0-6, especially because tumors grew more rapidly in depth after day 6 . Gross inspection of kidneys from CSA-treated mice after 10 days revealed healthy, discrete tumor grafts. In contrast, control tumors were difficult to measure because of hemorrhage and necrosis (Fig. 2) .
Growth of Murine Tumor Allografts. MBT-2 tumors grew in allogeneic CD-1 mice during the first 6 days after implantation (Fig. 3) , and no statistical difference in tumor size was observed on day 6 in allogeneic vs. syngeneic (G3H) mice. CSA treatment of CD-1 mice allowed tumor growth for 12 days that was not statistically different from tumor growth in syngeneic C3H mice. These results are similar to results with MX-1 human tumor xenografts in CSA-treated normal mice vs. nude mice. In these experiments MBT-2 tumor growth also was more rapid during days 6-12 than during days 0-6.
CSA treatments given to C3H mice implanted with syngeneic MBT-2 tumors had no detectable antitumor effect; in fact, a slight increase in tumor size was noted on day 12 in syngeneic mice (P < 0.05 for treated vs. controls). Similar results were obtained in two other experimental groups.
Histologic and Immunohistologic Studies. Although tumors increased in total size on day 6 in control mice, histological analysis revealed areas of inflammatory infiltrates and hemorrhagic necrosis (Fig. 4A) . In contrast, fragments from the same tumors in CSA-treated mice showed much less inflammation and necrosis even on days 6-12 (Fig. 4B) . The differences were similar for both mouse (MBT-2) and human (MX-1) tumors. Tumors in CSA-treated mice also showed prominent neovascularization and invasion of the kidney on days 6-12 after implantation, and some mice with allogeneic tumors had liver metastases. Although minor neovascular changes were observed on day 6 in control mice with allogeneic tumor grafts, only CSA-treated mice exhibited metastases or prominent tumor invasion into the kidney.
Immunoperoxidase staining with monoclonal antibodies revealed that a prominent portion of the cellular infiltrate consisted of host (murine) T cells (Fig. 4C) . Both suppressor T-cell subsets were observed on day 6 after tumor implantation into control mice, using anti-L3T3, antiLyti and anti-Lyt2 antibodies. Both T-cell subsets were dramatically reduced in CSA-treated mice. Antitumor Activity of cis-Pt. The capacity of the SRG assay to delineate antitumor activity of cis-Pt against growing MX-1 tumors was significantly improved when the drug was tested in GSA-treated mice (Fig. 5) . A single injection of cisPt (8 mg/kg) on day 1 in untreated mice produced a slight difference in tumor size observed on day 6 compared to controls ( Fig. SA) , but the difference was not statistically significant (P > 0.2). However, the same cis-Pt treatment given on day 6 to CSA-treated mice produced a much greater difference in tumor size by day 10 (P < 0.001 for treated vs. controls). Although an increase in control tumor size was observed on day 6 in CSA-treated mice (Fig. SB) , this difference was not statistically significant compared to mice without CSA (Fig. SA) . Similar results with cis-Pt were obtained in two additional experimental groups when CSA (80 mg/kg per day) was injected on days 1-5 after tumor implantation or when cis-Pt was given on day 1 before CSA (days 2-8).
DISCUSSION
We report that CSA allowed extended growth of human and rodent tumors in the SRC assay. The most rapid growth of implanted tumors in the SRC assay occurred after day 6, both in mice with syngeneic rodent tumors and in GSA-treated mice with human tumors. These results suggested that statistical discrimination of experimental treatments would be much improved [6] [7] [8] [9] [10] [11] [12] Slowly growing primary human tumor specimens from clinical biopsies may require longer growth periods (>10 days) for optimal discrimination of antitumor-drug activity, and the SRG assay in GSA-treated mice may make such studies feasible.
In contrast to other immunosuppressants, which have antineoplastic as well as antilymphocytic properties, GSA is highly selective against T cells, at doses that have no effect on tumor growth or bone marrow (9, 12, 13) . The rapid end point of the SRG assay allows brief GSA treatments, which have minimal toxicity to other vital host tissues. Using immunoperoxidase stains of tumors in the SRG assay, we observed that murine T cells were a prominent early component of the inflammatory response on days 6-10 after implantation. GSA effectively prevented T-cell infiltration, thereby improving reliability of tumor size (average diameters) for rapid quantification of total tumor cell growth. Our observations are consistent with previous studies of GSA in organ-transplant models, which showed selective immunosuppressive activity against T-cell function (9) and graft survival for extended periods after cessation of GSA treatment (12, 13) .
Using a transplanted rodent tumor in syngeneic mice, we found that GSA can be utilized in simple, daily regimens that have no antitumor effect per se, as previously shown with other syngeneic rodent tumors grown subcutaneously in GSA-treated animals (13) . Slightly increased growth of MBT-2 tumors in GSA-treated syngeneic mice also suggests that GSA could be used to improve growth of human tumors even in nude mice. GSA has been reported to inhibit naturalkiller-cell activity (14) , which may be important for growth or rejection of some xenografted tumors in athymic nude mice.
